生物制药用植物细胞培养平台商业化之路:现状与展望。

Jianfeng Xu, Ningning Zhang
{"title":"生物制药用植物细胞培养平台商业化之路:现状与展望。","authors":"Jianfeng Xu,&nbsp;Ningning Zhang","doi":"10.4155/pbp.14.32","DOIUrl":null,"url":null,"abstract":"<p><p>Plant cell culture is emerging as an alternative bioproduction system for recombinant pharmaceuticals. Growing plant cells <i>in vitro</i> under controlled environmental conditions allows for precise control over cell growth and protein production, batch-to-batch product consistency and a production process aligned with current good manufacturing practices. With the recent US FDA approval and commercialization of the world's first plant cell-based recombinant pharmaceutical for human use, β-glucocerebrosidase for treatment of Gaucher's disease, a new era has come in which plant cell culture shows high potential to displace some established platform technologies in niche markets. This review updates the progress in plant cell culture processing technology, highlights recent commercial successes and discusses the challenges that must be overcome to make this platform commercially viable.</p>","PeriodicalId":90285,"journal":{"name":"Pharmaceutical bioprocessing","volume":"2 6","pages":"499-518"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/pbp.14.32","citationCount":"81","resultStr":"{\"title\":\"On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.\",\"authors\":\"Jianfeng Xu,&nbsp;Ningning Zhang\",\"doi\":\"10.4155/pbp.14.32\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Plant cell culture is emerging as an alternative bioproduction system for recombinant pharmaceuticals. Growing plant cells <i>in vitro</i> under controlled environmental conditions allows for precise control over cell growth and protein production, batch-to-batch product consistency and a production process aligned with current good manufacturing practices. With the recent US FDA approval and commercialization of the world's first plant cell-based recombinant pharmaceutical for human use, β-glucocerebrosidase for treatment of Gaucher's disease, a new era has come in which plant cell culture shows high potential to displace some established platform technologies in niche markets. This review updates the progress in plant cell culture processing technology, highlights recent commercial successes and discusses the challenges that must be overcome to make this platform commercially viable.</p>\",\"PeriodicalId\":90285,\"journal\":{\"name\":\"Pharmaceutical bioprocessing\",\"volume\":\"2 6\",\"pages\":\"499-518\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4155/pbp.14.32\",\"citationCount\":\"81\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical bioprocessing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4155/pbp.14.32\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical bioprocessing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4155/pbp.14.32","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 81

摘要

植物细胞培养正在成为重组药物的一种替代生物生产系统。在受控的环境条件下体外培养植物细胞,可以精确控制细胞生长和蛋白质生产,批间产品一致性和符合当前良好生产规范的生产过程。最近,美国FDA批准了世界上第一个基于植物细胞的人用重组药物β-葡萄糖脑苷酶(β-glucocerebrosidase)的商业化,用于治疗戈谢病,一个新的时代已经到来,植物细胞培养显示出巨大的潜力,取代了利基市场上一些成熟的平台技术。这篇综述更新了植物细胞培养处理技术的进展,强调了最近的商业成功,并讨论了必须克服的挑战,使该平台在商业上可行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.

On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.

On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.

Plant cell culture is emerging as an alternative bioproduction system for recombinant pharmaceuticals. Growing plant cells in vitro under controlled environmental conditions allows for precise control over cell growth and protein production, batch-to-batch product consistency and a production process aligned with current good manufacturing practices. With the recent US FDA approval and commercialization of the world's first plant cell-based recombinant pharmaceutical for human use, β-glucocerebrosidase for treatment of Gaucher's disease, a new era has come in which plant cell culture shows high potential to displace some established platform technologies in niche markets. This review updates the progress in plant cell culture processing technology, highlights recent commercial successes and discusses the challenges that must be overcome to make this platform commercially viable.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信